Evidence of SLFN11 as a patient stratification biomarker for DDA in clinical indications beyond SCLC is limited, although supportive clinical data were reported in oesophageal, gastric and TNBC [8, 12, 13]. Here, SLFN11 is linked to small cell lung carcinoma.